Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicament composition containing losartan and hydrochlorothiazidum

A technology of hydrochlorothiazide and losartan potassium, which is applied in the direction of drug combination, medical preparations containing active ingredients, medical preparations without active ingredients, etc., can solve the problems of content reduction, increase of related substances, poor stability of hydrochlorothiazide, etc., and achieve The effect of good stability

Inactive Publication Date: 2013-02-27
BEIJING D VENTUREPHARM TECH DEV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

On the other hand, the stability of hydrochlorothiazide is poor, and it is easy to reduce the content and increase the related substances after it is made into a preparation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament composition containing losartan and hydrochlorothiazidum
  • Medicament composition containing losartan and hydrochlorothiazidum
  • Medicament composition containing losartan and hydrochlorothiazidum

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017]

[0018]

[0019] Preparation:

[0020] (1) Place the prescription amount of hydrochlorothiazide and lactose in a high-speed pulverizer to pulverize to obtain mixture I;

[0021] (2) Add prescription amounts of losartan potassium and sodium alginate to the mixture I in equal increments, and mix to obtain a pharmaceutical composition.

[0022] (3) adding prescription amount of starch and microcrystalline cellulose to the pharmaceutical composition to obtain mixture II;

[0023] (4) Add appropriate amount of wetting agent water to the mixture II, make soft material, pass through a 24-mesh sieve to granulate;

[0024] (5) After drying at 50°C, pass through a 30-mesh sieve for granulation;

[0025] (6) take magnesium stearate and dry granule and mix by recipe quantity to obtain mixture III;

[0026] (7) Fill the mixture III into the No. 1 capsule, and that's it.

Embodiment 2

[0028]

[0029] Preparation:

[0030] (1) Place the prescription amount of hydrochlorothiazide and lactose in a high-speed pulverizer to pulverize to obtain mixture I;

[0031] (2) Add prescription amounts of losartan potassium and sodium alginate to the mixture I in equal increments, and mix to obtain a pharmaceutical composition.

[0032] (3) adding prescription amount of starch and microcrystalline cellulose to the pharmaceutical composition to obtain mixture II;

[0033] (4) Add appropriate amount of wetting agent water to the mixture II, make soft material, pass through a 24-mesh sieve to granulate;

[0034] (5) After drying at 50°C, pass through a 30-mesh sieve for granulation;

[0035] (6) take magnesium stearate and dry granule and mix by recipe quantity to obtain mixture III;

[0036] (7) Compress mixture III on a tablet machine.

Embodiment 3

[0038]

[0039] Preparation:

[0040] (1) Place the prescription amount of hydrochlorothiazide and lactose in a high-speed pulverizer to pulverize to obtain mixture I;

[0041] (2) Add prescription amounts of losartan potassium and sodium alginate to the mixture I in equal increments, and mix to obtain a pharmaceutical composition.

[0042] (3) adding prescription amount sucrose and microcrystalline cellulose to the pharmaceutical composition to obtain mixture II;

[0043] (4) Add an appropriate amount of wetting agent water to the mixture II, make soft material, pass through a 16-mesh sieve and granulate;

[0044] (5) After drying at 50°C, sieve through a 30-mesh sieve for granulation, and pack them separately.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicine composition containing losartan potassium and hydrochlorothiazide and a preparation method thereof. The composition also contains auxiliary materials, namely sodium alginate and lactose. The medicine composition can be prepared into capsules, tablets, granules and so on after being added with other proper pharmaceutic adjuvant.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing losartan and hydrochlorothiazide and a preparation method thereof. The pharmaceutical composition also contains lactose and sodium alginate. Background technique [0002] Due to the improvement of people's living standards and the increasingly tense job competition, the number of patients with hypertension has greatly increased. The prevalence of hypertension in my country has increased significantly. According to statistics in China, the incidence of hypertension among Chinese people aged 35 to 74 is as high as 27%. Hypertension can cause damage to the heart, brain, kidney and other organs, seriously threatening human health and life. [0003] Losartan Potassium is the first-generation oral non-peptide angiotensin II receptor inhibitor developed and marketed by Merck. It was first launched in Sweden in 1994 and officially launched in my country in 1998. It is now available in more than ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/549A61K9/16A61K9/20A61K9/48A61K47/36A61P9/12A61K31/4178
Inventor 宋扬
Owner BEIJING D VENTUREPHARM TECH DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com